Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2020 Earnings Conference Call - Final Transcript
May 21, 2020 • 04:30 pm ET
Ladies and gentlemen, thank you for standing by and welcome to the Q1 2020, Xenon Pharmaceuticals Earnings Conference Call. [Operator Instructions] After the speakers presentation there will be a question-and-answer session. [Operator Instructions].
I would now like to hand the conference over to your speaker today, Ms. Jodi Regts. Thank you. Please go ahead ma'am.
Thank you. Good afternoon. Thank you for joining us on our call and webcast to discuss our first quarter 2020 financial and operating results. Joining me on today's call are Dr. Simon Pimstone, Xenon's Chief Executive Officer; and Ian Mortimer, Xenon's President and Chief Financial Officer. Following this introduction, Simon will give an overview of Xenon's clinical programs, and then Ian will provide some high level financial commentary. After that, we will open up the call to your questions.
Please be advised that during this call we will make a number of statements that are forward-looking, including statements regarding the anticipated impact and timing of the COVID-19 pandemic on our business, research and clinical development plans and timelines and results of operations; the timing of and results from clinical trials and preclinical development activities of proprietary and partnered product candidates; the potential efficacy, safety profile, future development plans, addressable market, regulatory success and commercial potential of proprietary and partnered product candidates.
The anticipated timing of IND or IND equivalent submissions and the initiation of future clinical trials for proprietary and partner candidates; the efficacy of our clinical trial designs; our ability to successfully develop and achieve milestones in the XEN496, XEN1101 and XEN007 and other proprietary development programs; the timing and results of our interactions with regulators; the potential to advance certain of our product candidates directly into Phase 2 or later-stage clinical trials; anticipated enrollment in our clinical trials and the timing thereof; the progress and potential of our ongoing development programs; the potential receipt of milestone payments and royalties from our collaborators; our expectation of having sufficient cash to fund operations into 2022; and the timing of potential publication or presentation of future clinical data.
Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time-to-time in our SEC filings. Our results may differ materially from those projected on today's call. We undertake no obligation to publicly update any forward-looking statements.
Today's press release summarizing the results of Xenon's first quarter of 2020 and the accompanying quarterly report on Form 10-Q will be made available under the Investor section of our website at www.xenon-pharma.com and filed with the SEC and on SEDAR.
Now, I would like to turn the call over to Simon.
Thank you, Jodi, and good afternoon everyone and thank you all for joining us today. At the end of March we issued a statement outlining our response to the COVID-19 pandemic. Xenon continues to put the safety and wellbeing of people first, including the clinicians and patients involved in our clinical trials, as well our employees and their